Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Rudqvist, Nils-Petter; Avagyan, Manushak; Chand, Dhan

doi:10.1080/2162402x.2023.2275333

Cited by 3 publications

(1 citation statement)

References 10 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar fashion, another CTLA-4 targeting ICI, namely tremelimumab, was approved by the Food and Drug Administration in combination regimens in the setting of HCC [35] and NSCLC [36]. Further anti-CTLA-4 monoclonal antibodies are still under development, aimed at increasing the efficacy of such agents when administered as monotherapies, while reducing the risk of side effects [37].…”

Section: Immunotherapy: From Concept To Clinical Applicationmentioning

confidence: 99%

Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows

Silvestris,

D’Oronzo,

Petracca

et al. 2024

JPM

View full text Add to dashboard Cite

In recent years, immuno-oncology has revolutionized the cancer treatment field by harnessing the immune system’s power to counteract cancer cells. While this innovative approach holds great promise for improving cancer outcomes, it also raises important considerations related to fertility and reproductive toxicity. In fact, most young females receiving gonadotoxic anti-cancer treatments undergo iatrogenic ovarian exhaustion, resulting in a permanent illness that precludes the vocation of motherhood as a natural female sexual identity. Although commonly used, oocyte cryopreservation for future in vitro fertilization and even ovarian cortex transplantation are considered unsafe procedures in cancer patients due to their oncogenic risks; whereas, ovarian stem cells might support neo-oogenesis, providing a novel stemness model of regenerative medicine for future fertility preservation programs in oncology. Recent scientific evidence has postulated that immune checkpoint inhibitors (ICIs) might in some way reduce fertility by inducing either primary or secondary hypogonadism, whose incidence and mechanisms are not yet known. Therefore, considering the lack of data, it is currently not possible to define the most suitable FP procedure for young patients who are candidates for ICIs. In this report, we will investigate the few available data concerning the molecular regulation of ICI therapy and their resulting gonadal toxicity, to hypothesize the most suitable fertility preservation strategy for patients receiving these drugs.

show abstract

Section: Immunotherapy: From Concept To Clinical Applicationmentioning

confidence: 99%